Clinical Trial Update: Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a combination therapy (rucaparib + ramucirumab with or without nivolumab) in advanced gastric and esophageal adenocarcinoma across Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Stomach Adenocarcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)
• Rucaparib (rucaparib)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN